1. Home
  2. SYBX vs NCNA Comparison

SYBX vs NCNA Comparison

Compare SYBX & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Synlogic Inc.

SYBX

Synlogic Inc.

N/A

Current Price

$1.12

Market Cap

15.2M

Sector

Health Care

ML Signal

N/A

Logo NuCana plc

NCNA

NuCana plc

HOLD

Current Price

$3.38

Market Cap

13.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SYBX
NCNA
Founded
N/A
1997
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.2M
13.8M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
SYBX
NCNA
Price
$1.12
$3.38
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
27.8K
76.5K
Earning Date
03-05-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.90
$2.78
52 Week High
$1.96
$268.00

Technical Indicators

Market Signals
Indicator
SYBX
NCNA
Relative Strength Index (RSI) 39.48 41.54
Support Level $1.17 $3.25
Resistance Level $1.23 $3.81
Average True Range (ATR) 0.05 0.22
MACD 0.01 -0.00
Stochastic Oscillator 11.76 27.69

Price Performance

Historical Comparison
SYBX
NCNA

About SYBX Synlogic Inc.

Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.

About NCNA NuCana plc

NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.

Share on Social Networks: